Drug profile · INN
cannabidiol
EPIDYOLEX
cannabidiol (EPIDYOLEX) is a cannabinoid cb1 receptor negative allosteric modulator. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — cannabidiol
- US status
- approved
- Class
- Nervous system (N03)
- Route
- ORAL
- Patents
- 20
- Programs
- 28
- Data quality
- 0.89
Quick answer
cannabidiol (EPIDYOLEX) is a cannabinoid cb1 receptor negative allosteric modulator. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cannabinoid CB1 receptor negative allosteric modulator
Primary target: Cannabinoid receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12419888
Methods of treating elevated plasma cholesterol
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12263139
Use of cannabidiol in the treatment of tuberous sclerosis complex
granted -
US 12226373
Treatment of fragile X syndrome with cannabidiol
granted -
US 12213951
Treatment of autism with cannabidiol
granted -
US 12186282
Treatment of 22Q11.2 deletion syndrome with cannabidiol
granted -
US 12102619
Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
granted -
US 12064399
Use of cannabinoids in the treatment of epilepsy
granted -
US 11826428
Solid solution compositions comprising cannabidiols
granted -
US 11712474
Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition
granted -
US 11639490
Device and method for producing and purifying exosomes
granted -
US 11364202
Solid forms of cannabidiol and uses thereof
granted -
US 11285184
Cannabidiol alkaline composition
granted -
US 10870632
Process for producing an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material, and cannabis extracts
granted -
US 10788490
Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits
granted -
US 10722581
Phonophoretic cannabidiol composition and transdermal delivery system
granted -
US 10604467
Solid forms of cannabidiol and uses thereof
granted
Frequently asked questions
What is cannabidiol?
cannabidiol (EPIDYOLEX) is a cannabinoid cb1 receptor negative allosteric modulator. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cannabidiol?
EPIDYOLEX is a marketed brand name for cannabidiol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cannabidiol?
cannabidiol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.